The stock of Norwegian contrast agent developer Nycomed rose on the Oslo stock exchange this month on rumors that the company was exploring closer ties with German pharmaceutical company Altana Industrie-Aktien und Anlagen. The companies are already
The stock of Norwegian contrast agent developer Nycomed rose on the Oslo stock exchange this month on rumors that the company was exploring closer ties with German pharmaceutical company Altana Industrie-Aktien und Anlagen. The companies are already jointly marketing an ulcer drug, and may be looking for ways to expand their partnership, according to AFX News.
Nycomed has been the subject of merger or acquisition rumors since its proposed merger with U.S. generic drug firm Ivax broke down in 1995 (SCAN 12/13/95). The company said at the time the deal fell apart that it would continue to pursue strategic partnerships. Nycomed executives declined to comment on the Altana rumors.
Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
January 31st 2025A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.
Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
January 31st 2025A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.
2 Commerce Drive
Cranbury, NJ 08512